This randomized, double-blinded and placebo-controlled trial was performed following the approval by the ethics committee of Guilan University of Medical Sciences, Guilan, Iran, under registration (IR.GUMS.REC.1395.396) and recorded by the International Center for Registration of Clinical Trials in Iran (code IRCT201705214295N3). The study was conducted on 118 students residing in the Kowsar dormitory of Guilan University of Medical Sciences. The inclusion criteria were as follows: being single, regular menstrual cycles of 21 - 35 days, no physical or psychological ill conditions, not on medication (hormones, vitamins, herbal, anti-depressant, aspirin, or Warfarin), no history of allergy to herbal drugs, no surgical operation during the last six months, not being a professional athlete. Those with the above-mentioned criteria were entered into the study. Informed written consent was also given by each participant. Exclusion Criteria: The exclusion criteria included: improper use of capsules, allergy to drugs, unwillingness to continue participation in the study and receiving and taking medications during the study. 118 students entered into the study, then, participants were randomly divided into 2 equal groups of intervention (N: 59) and control (N: 59).
Tools for data collection were: Pictorial blood loss assessment charts. The women were asked to record the number of pads and tampons used and the degree to which individual items were soiled with blood. The score calculated by multiplying the number of slightly, moderately, and heavily soiled pads and tampons by different fixed factors (respectively, one, five, and 20 for pads and one, five, and 10 for tampons). Small clots score one point, and large clots, five points. In doing so, Total scores were calculated, and based on the amount of the overall score of menstrual flow were evaluated. The women also were asked to indicate the duration of flows and cycles. The demographic questionnaire: It consisted of 3 demographic items about their age, weight, height and 3 questions related to menarche, duration of menses, and menstrual interval. Content validity was used to assess the validity of the tools. In doing so, the questionnaires were prepared based on the research goal and relevant scientific sources and consultation with ten experts. The required revisions and changes were made to the questionnaire, as suggested by the expert reviewers.
Once the definitive diagnosis of the amount and duration of menstrual flow was made, the participants were randomly divided into two groups. Chamomile group: The participants received Chamomile capsule received 250 mg, and the placebo group received a placebo capsule, all participants received capsules from 7 days prior to menstrual bleeding till the next onset of menstruation period, three times daily for one cycle.
The Chamomile and placebo capsules were prepared with an identical appearance by the Barij Essence pharmaceutical company (Kashan, Iran. Chamomile powder as the drug was prepared through drying the aerial organ of the plant, and capsules containing 250 mg of the obtained powder were prepared. The starch powder as a placebo was filled in oral capsules. The two types of capsules were put in separate coded packs by the pharmacy and participants were blinded to the type of the ingredients.
Once the questionnaires were collected following each period, the respective data were obtained and analyzed by statistical tests. SPSS version 23 was used along with descriptive statistical techniques such as frequency table, means values, the standard deviation to evaluate the efficacy of the treatments and associated side effects on the recipients. Inferential statistical tests such as independent t, paired sample t-test, Wilcoxon signed-rank test, Chi-square, Mann Whitney test was used to make intergroup and intragroup comparisons in terms of intensity of the amount and duration of menstrual bleeding. A P-value of less than 0.05 was considered significant.